4.7 Review

Updated Clinical Classification of Pulmonary Hypertension

期刊

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2013.10.029

关键词

chronic thromboembolic pulmonary hypertension; PH due to chronic lung diseases; PH due to left heart disease; pulmonary arterial hypertension; pulmonary hypertension

资金

  1. Actelion
  2. Pfizer
  3. Bayer-Schering
  4. GlaxoSmithKline
  5. Novartis
  6. Eli Lilly
  7. Pfizer UK
  8. Digna
  9. Sanofi Aventis
  10. Boehringer Ingelheim
  11. Roche
  12. CSL Behring
  13. Genzyme
  14. Encysive
  15. Merck
  16. Myogen
  17. NHLBI
  18. United Therapeutics
  19. Bayer
  20. Lilly
  21. Gilead
  22. Unither
  23. NebuTec

向作者/读者索取更多资源

In 1998, a clinical classification of pulmonary hypertension (PH) was established, categorizing PH into groups which share similar pathological and hemodynamic characteristics and therapeutic approaches. During the 5th World Symposium held in Nice, France, in 2013, the consensus was reached to maintain the general scheme of previous clinical classifications. However, modifications and updates especially for Group 1 patients (pulmonary arterial hypertension [PAH]) were proposed. The main change was to withdraw persistent pulmonary hypertension of the newborn (PPHN) from Group 1 because this entity carries more differences than similarities with other PAH subgroups. In the current classification, PPHN is now designated number 1. Pulmonary hypertension associated with chronic hemolytic anemia has been moved from Group 1 PAH to Group 5, unclear/multifactorial mechanism. In addition, it was decided to add specific items related to pediatric pulmonary hypertension in order to create a comprehensive, common classification for both adults and children. Therefore, congenital or acquired left-heart inflow/outflow obstructive lesions and congenital cardiomyopathies have been added to Group 2, and segmental pulmonary hypertension has been added to Group 5. Last, there were no changes for Groups 2, 3, and 4. (C) 2013 by the American College of Cardiology Foundation

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据